Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis
Peter BB Jones1,2, Douglas HN White21Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 2Rheumatology Department, Waikato Hospital, Hamilton, New ZealandAbstract: Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been in routine clinical use...
Enregistré dans:
Auteurs principaux: | Peter BB Jones, Douglas HN White |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2010
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7d7a87290fc4437c8b3c13f26dd4880b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
par: Fabrizio Cantini, et autres
Publié: (2009) -
Optimal management of dactylitis in patients with psoriatic arthritis
par: Yamamoto T
Publié: (2015) -
Update on the use of rituximab for intractable rheumatoid arthritis
par: R John Looney
Publié: (2009) -
Rheumatoid arthritis: Disease or syndrome?
par: Jessica A Stanich, et autres
Publié: (2009) -
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
par: Montepaone M, et autres
Publié: (2014)